Publications for Marc K. Wallack marc_wallack@nymc.edu
Akram, W., Degliuomini, J., Wallack, M. K., Huang, S., Okechukwu, E., & Eric, T. (2016). Unicentric castleman's disease masquerading as a carcinoid tumor of the small intestine. The American Surgeon, 82(9), e287-e289.
George, A. L., Suriano, R., Rajoria, S. , Geliebter, J., Arnold, A. N., Wallack, M., . . . Tiwari, R. K. (2015). PLX4032 mediated melanoma associated antigen potentiation in patient derived primary melanoma cells. Journal of Cancer, 6(12), 1320-1330. doi:10.7150/jca.11126
Suriano, R., Tuli, N., Geliebter, J., Tiwari, R. K., & Wallack,M. K. (2014). Targeted inhibition of BRAF signaling in melanoma enhances the activity of a multivalent immunotherapeutic vaccine. Cancer Research, 74(19 Suppl.), 641.
Wallack, M., Suriano, R., Tuli, N., George, A. L., Geliebter, J., & Tiwari, R. K. (2014). Clinical utility of combining PLX4032, a BRAF inhibitor, with a multivalent melanoma immunotherapeutic vaccine. Annals of Surgical Oncology, 21(1 Suppl.), S124.
Donaire, M., Mariadason, J., Stephens, D., Pillarisetty, S., & Wallack, M. K. (2013). Carcinoma of the colon in an adult with intestinal malrotation. Case Reports in Surgery, 2013 [Article 525081]. doi:10.1155/2013/525081
Suriano, R., Rajoria, S., George, A. L., Geliebter, J., Tiwari, R. K., & Wallack, M. K. (2013). Follow-up analysis of a randomized phase III immunotherapeutic clinical trial on melanoma. Molecular Clinical Oncology, 1(3), 466-472. doi:10.3892/mco.2013.97
Suriano, R., Rajoria, S., George, A. L., Geliebter, J., Wallack, M. K., & Tiwari, R. K. (2013). Ex vivo derived primary melanoma cells: Implications for immunotherapeutic vaccines. Journal of Cancer, 4(5), 371-382. doi:10.7150/jca.6625
